Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

 
• By Aidan Fry

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Nasal_Spray
Hikma is looking to bring anaphylaxis treatment epinephrine and the opioid overdose drug naloxone to the US market as unit-dose nasal sprays • Source: Shutterstock

More from Value Added Medicines

More from Products